No abstract

No abstract

Background Implantable cardioverter defibrillator (ICD) acceptance and shock anxiety are issues that clinicians should address to improve quality of life among device recipients. Previous findings have indicated that younger patients experience poorer device adjustment. The purpose of this study was to examine age and ICD-specific quality-of-life outcomes in a large sample of Canadian ICD patients. We tested the hypothesis that patient age is related to device acceptance and shock anxiety in an Alberta (Canada) ICD population. Methods The Florida Patient Acceptance Survey (FPAS) and Florida Shock Acceptance Survey (FSAS) were completed by ICD patients attending the Cardiac Implantable Electrical Device Clinics in Alberta. The population was dichotomized into those aged ≤ 65 years (younger) and those aged > 65 years (older). Sex, ICD shock history, and remote monitoring use were also examined. Results Surveys were completed by 126 younger (53 ± 11 years; 79% male) and 216 older (74 ± 6 years; 85% male) patients. Younger, compared with older, patients had greater device-related distress ( P < 0.001) and more body-image concerns ( P < 0.001), but no differences in return to function or positive appraisal. Younger patients reported lower total device acceptance ( P = 0.001) and greater total shock anxiety ( P < 0.001) compared with older patients. Conclusions ICD patients aged ≤ 65 years reported poorer device acceptance and greater shock anxiety than older patients. Younger patients may require targeted interventions addressing adjustment to the ICD, and impact of the ICD on body image. Moreover, education about the relatively low probability of shocks may alleviate shock anxiety in younger patients.

phase. Isolation of the products was accomplished by extraction of the silica gel with ether, filtration, and evaporation of the ether. The material with the largest R¡ value (0.91), ester 3c, was recovered in 6% yield (3 mg). The material with the second largest R¡ value (0.73), (±)-tabersonine, was isolated as a clear semisolid, 15 mg (30.2%), and was identical with a sample of natural origin by comparative tic, solution infrared, ultraviolet, and mass spectrometry.When the polar material isolated from the preparative tic plate (25 mg) was stirred overnight in 5% aqueous acetic acid, an additional 7 mg (total yield of 44.5%) of tabersonine was obtained.Acknowledgment. The authors wish to express their appreciation to the Natural Science Foundation (GP-11273) for their generous support of this work.